Cell line/type | EPCs (endothelial progenitor cells) |
---|---|
Species | Human |
Animal free | No |
Product | StemSpan SFEM |
Masuda, H., Iwasaki, H., Kawamoto, A., Akimaru, H., Ishikawa, M., Ii, M., ... & Ishida, H. (2012). Development of serum‐free quality and quantity control culture of colony‐forming endothelial progenitor cell for vasculogenesis. Stem cells translational medicine, 1(2), 160-171. In this study, a serum-free quality and quantity control culture system for colony-forming EPCs was developed to enhance their regenerative potential. A culture with serum-free medium containing stem cell factor, thrombopoietin, vascular endothelial growth factor, interleukin-6, and Flt-3 ligand was determined as optimal quality and quantity culture (QQc) in terms of the most vasculogenic colony-forming EPC expansion, evaluated by the newly established EPC colony formation assay. The QQc of umbilical cord blood-CD133(+) cells for 7 days produced a 52.9-fold increase in total cell number and 3.28-fold frequency in definitive EPC colony development, resulting in a 203.9-fold increase in estimated total definitive EPC colony number in vitro. Pre- or post-QQc cells were intramyocardially transplanted into nude rats with myocardial infarction (MI). Echocardiographic and micromanometer-tipped conductance catheter examinations 28 days post-MI revealed significant preservation of left ventricular (LV) function in rats receiving pre- or post-QQc cells compared with those receiving phosphate-buffered saline. Assessments of global LV contractility indicated a dose-dependent effect of pre- or post-QQc cells and the superior potency of post-QQc cells over pre-QQc cells. Furthermore, immunohistochemistry showed a more abundant formation of both human and rat endothelial cells and cardiomyocytes in the infarcted myocardium following transplantation of post-QQc cells compared with pre-QQc cells. THis optimal serum-free quality and quantity culture may enhance the therapeutic potential of EPCs in both quantitative and qualitative aspects for cardiovascular regeneration. StemSpan SFEM is a commercial product. The formulation is proprietary. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3659679/pdf/sct160.pdf |
|
Source | Literature - commercial |
Chemically defined > Yes | Yes |